Pharmaceutical sales for the third quarter of 2020 at Roche Holding AG have fallen well short of consensus estimates, with its trio of big-selling cancer drugs – Avastin, MabThera/Rituxan and Herceptin – continuing to be battered by biosimilars but newer products such as Ocrevus and Hemlibra enjoyed healthy growth despite the impact of COVID-19.
Tough Q3 For Roche But Diagnostics Soften The Blow
Biosimilar Competition Keeps Biting
The Swiss major's old guard of oncology products continue to falter but Roche's new wave of treatments is helping to keep the financials fairly healthy.
More from Earnings
• By
AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.
• By
The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.
• By
Adstiladrin sales hit €70m in first full year on the market
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
More from Business
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
• By
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.
• By
Restructuring Edition: ESSA and Elevation are reviewing strategic alternatives after trial failures, but each has an investor urging them to liquidate. Also, Third Harmonic and Vincerx are winding down, while Keros and Tempest are assessing options, but Opthea and OPM are cutting jobs.